Navigation Links
Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
Date:5/3/2012

HAYWARD, Calif., May 3, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended March 31, 2012.

Financial Results:

Total operating expenses for the first quarter ended March 31, 2012 were $20.1 million, as compared to $28.4 million for the fourth quarter ended December 31, 2011. The decrease in operating expenses can be primarily attributed to the completion of enrollment of the PEARL-SC study in the fourth quarter. The Company expects operating expenses to decline further in subsequent quarters following the discontinuation of varespladib development.

Anthera ended the first quarter of 2012 with approximately $44.0 million in cash and cash equivalents and short-term investments.  This is compared to $67.4 million in cash and cash equivalents and short-term investments for the fourth quarter ended December 31, 2011. The Company expects cash burn for the second quarter ended June 30, 2012 to be approximately $13.0-15.0 million.

Anthera will host a conference call at 8:30 a.m. Eastern Time tomorrow, May 4, 2012. U.S. and Canadian participants may dial (877) 312-8807; international participants may dial (253) 237-1190.  The Conference ID is 76225935. To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406.  The conference ID for the replay is 76225935.  The audio replay will be available until May 11, 2012.

Recent Business Highlights and Upcoming Events:

Clinical

  • The PEARL-SC Data Safety Monitoring Board (DSMB) met for the fourth time to review available safety data and recommended the study continue without change. The PEARL-SC study is examining the therapeutic benefit of monthly and weekly subcutaneous doses of blisibimod in p
    '/>"/>

  • SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
    2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
    3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
    5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
    6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
    8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
    9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
    11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... MOUNTAIN VIEW, Calif. , July 29, 2014 ... antivirals has amplified with rising incidence rates and ... absence of a preventative vaccine. Change is underway ... and interferon regimens towards highly effective, easily-tolerated, interferon-free ... http://photos.prnewswire.com/prnh/20140728/130662 Gilead,s mega blockbuster ...
    (Date:7/29/2014)... 29, 2014  Cloud Pharmaceuticals, Inc., a therapeutics ... announced today that it has been awarded a ... Small Business Innovation Research (NSF SBIR) program. The ... Cloud Pharmaceuticals designs new drugs and drug candidates ... innovative cloud computing technology in place of traditional ...
    (Date:7/29/2014)... 29, 2014  Encision Inc. (OTCQB:ECIA), a medical device ... electrosurgical burns in minimally invasive surgery, today announced financial ... 30, 2014. The Company posted quarterly net ... of $202 thousand, or $(0.02) per share. These results ... net loss of $311 thousand, or $(0.04) per share, ...
    Breaking Medicine Technology:A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4Cloud Pharmaceuticals Receives Phase I NSF SBIR Grant Valued at $150,000 2Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4
    ... 15, 2011  SuccessEHS announces the release of the new ... equip clients with a dependable roadmap to NCQA ... the meaningful use criteria. The release of ... solution that support the patient-centered care model, and underscores ...
    ... Dec. 15, 2011  New York Gov. Andrew Cuomo,s pen was ... law a bill that bans Pharmacy Benefit Managers (PBMs) from ... Cuomo and the New York State Assembly showed tremendous courage ... hundreds of thousands of dollars lobbying against the new law. ...
    Cached Medicine Technology:SuccessEHS Releases Patient-Centered Medical Home (PCMH) Toolkit 2SuccessEHS Releases Patient-Centered Medical Home (PCMH) Toolkit 3SuccessEHS Releases Patient-Centered Medical Home (PCMH) Toolkit 4New York's Anti-Mandatory Mail Order Law Underscores Growing Skepticism of PBMs 2
    (Date:7/29/2014)... Mach7 Technologies, an award-winning provider of ... of an enhanced version of its Physician & ... & Patient Portal enables direct communication and collaboration ... a comprehensive view of their care history, including ... care records and intelligently delivers access to records ...
    (Date:7/29/2014)... Jessup, PA (PRWEB) July 29, 2014 ... Business Process Outsourcing solutions for health plans in ... and Managed Medicaid markets recently held its annual ... Jessup, Pa. Under the conference theme, “Partners in ... convened management executives and operations leaders from TMG ...
    (Date:7/29/2014)... assistant professors at the Virginia Tech Carilion Research ... Commonwealth Health Research Board to investigate hereditary breast ... approaches. , The board funds research intended to benefit ... project to study the mechanisms behind hereditary breast cancer ... often has a poor outcome, especially in Virginians compared ...
    (Date:7/29/2014)... On Friday, the United States Senate ... of October 12-18, 2014, as "National Case Management Week" ... healthcare outcomes for patients. The resolution was introduced by ... with support by the Case Management Society of America ... management professionals for their contributions to healthcare. , “Case ...
    (Date:7/29/2014)... 2014 “Approximately 18% of our population ... common chronic illnesses,” Western Washington Medical Group says in ... for those suffering from allergies to seek medical attention. ... care each year in the United States,” they continue. ... of life for themselves, rather than seeking the appropriate ...
    Breaking Medicine News(10 mins):Health News:Mach7 Technologies’ Physician & Patient Portal Consolidates Patient Care Records across the Enterprise and Simplifies Image Sharing and Communication 2Health News:Mach7 Technologies’ Physician & Patient Portal Consolidates Patient Care Records across the Enterprise and Simplifies Image Sharing and Communication 3Health News:TMG Health Client Forum Explores Strategies for Success in the Post-Reform Market 2Health News:TMG Health Client Forum Explores Strategies for Success in the Post-Reform Market 3Health News:Scientists to study hereditary breast cancer to find BRCA1 treatment 2Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 3
    ... 26 ( www.amdl.com ) China continues to show ... Inc. (NYSE Alternext US: ADL) Chairman and CEO Mr. ... of an internal economic forecast research report indicating China ... the world, eclipsing every other international market.Mr. MacLellan has ...
    ... NEW YORK, Jan. 26 The National Center on ... announced today that Bruce E. Mosler has been ... ) , Mosler, president and CEO of Cushman ... estate services firm and serves on its board of ...
    ... hard work and dedication to the highest quality of care ... ... 26, 2009 -- Sierra Tucson, a premier treatment center dedicated ... disorders, today announced the achievement of accreditation as a "Hospital" ...
    ... LOUIS, Jan. 26 KV Pharmaceutical,(NYSE: KVa/KVb) has voluntarily suspended ... certain products that it distributes but does,not manufacture. The ... Additionally, the company will conduct a voluntary recall of ... recall are currently under discussion,with the U.S. Food and Drug ...
    ... Mass., Jan. 26 Instrumentation Laboratory (IL) today ... its contract to offer IL,s critical care portfolio ... history between the two companies, whose original contract ... of critical care analyzers, reagents, consumables and service, ...
    ... Medimetriks Pharmaceuticals announced today that the Company has ... PRGO ), a leading manufacturer in the ... Distributor of generic versions of Medimetriks, branded products in ... receive a percentage of Perrigo,s Net Sales on the ...
    Cached Medicine News:Health News:AMDL, Inc. Chairman & CEO Announces Expert Opinion on China's Economic Forecast 2Health News:Bruce E. Mosler, President and CEO of Cushman & Wakefield Elected to CASA* Board 2Health News:Bruce E. Mosler, President and CEO of Cushman & Wakefield Elected to CASA* Board 3Health News:Sierra Tucson Achieves Hospital Accreditation, Now Holds Dual Accreditation by the Joint Commission 2Health News:KV Pharmaceutical Suspends Product Manufacturing, Shipping 2Health News:KV Pharmaceutical Suspends Product Manufacturing, Shipping 3Health News:KV Pharmaceutical Suspends Product Manufacturing, Shipping 4Health News:KV Pharmaceutical Suspends Product Manufacturing, Shipping 5Health News:Instrumentation Laboratory Wins Extended Agreement With MedAssets Supply Chain Systems for Critical Care Portfolio 2Health News:Instrumentation Laboratory Wins Extended Agreement With MedAssets Supply Chain Systems for Critical Care Portfolio 3Health News:Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals 2Health News:Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals 3
    ... Used for catheter or instrument ... features a fabrication process that eliminates ... and introducer dilator, facilitating introduction through ... reinforcement sleeve prevents movement between introducer ...
    ... Used for temporary internal ... junction to the bladder. ... packages. Intended for one-time ... is advised; C-Flex® and ...
    ... or instrument introduction. The dual knobs ... away and removed. The maximum diameter ... be introduced should be measured to ... Supplied sterile in peel-open packages. Intended ...
    Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
    Medicine Products: